In order to address and implement a successful AM- or NF-kB inhibitor-based treatment for AD “highly individualistic” or “personalized” treatment strategies may be required to more effectively address the specific miRNA deficits of each AD patient, including combinatorial and/or tailored AM strategies that will take dedicated care and customization to ensure a successful clinical outcome. This evidence concerns the gene NFKB1 and Alzheimer disease.